vs
ANI PHARMACEUTICALS INC（ANIP）与Liberty Broadband Corp（LBRDA）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是ANI PHARMACEUTICALS INC的1.1倍（$261.0M vs $247.1M），Liberty Broadband Corp净利率更高（146.7% vs 11.1%，领先135.6%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 6.1%），Liberty Broadband Corp自由现金流更多（$37.0M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 4.3%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
ANIP vs LBRDA — 直观对比
营收规模更大
LBRDA
是对方的1.1倍
$247.1M
营收增速更快
ANIP
高出23.5%
6.1%
净利率更高
LBRDA
高出135.6%
11.1%
自由现金流更多
LBRDA
多$7.9M
$29.1M
两年增速更快
ANIP
近两年复合增速
4.3%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $261.0M |
| 净利润 | $27.5M | $383.0M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | 15.7% |
| 净利率 | 11.1% | 146.7% |
| 营收同比 | 29.6% | 6.1% |
| 净利润同比 | 367.5% | 96.4% |
| 每股收益（稀释后） | $1.14 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPLBRDA
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | — | ||
| Q2 25 | $211.4M | $261.0M | ||
| Q1 25 | $197.1M | $266.0M | ||
| Q4 24 | $190.6M | $263.0M | ||
| Q3 24 | $148.3M | $262.0M | ||
| Q2 24 | $138.0M | $246.0M | ||
| Q1 24 | $137.4M | $245.0M |
净利润ANIPLBRDA
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | — | ||
| Q2 25 | $8.5M | $383.0M | ||
| Q1 25 | $15.7M | $268.0M | ||
| Q4 24 | $-10.3M | $291.0M | ||
| Q3 24 | $-24.2M | $142.0M | ||
| Q2 24 | $-2.3M | $195.0M | ||
| Q1 24 | $18.2M | $241.0M |
营业利润率ANIPLBRDA
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 6.6% | 15.7% | ||
| Q1 25 | 13.3% | 16.2% | ||
| Q4 24 | -2.3% | 4.9% | ||
| Q3 24 | -13.8% | 11.5% | ||
| Q2 24 | 3.7% | 8.5% | ||
| Q1 24 | 14.8% | 11.4% |
净利率ANIPLBRDA
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 4.0% | 146.7% | ||
| Q1 25 | 8.0% | 100.8% | ||
| Q4 24 | -5.4% | 110.6% | ||
| Q3 24 | -16.3% | 54.2% | ||
| Q2 24 | -1.7% | 79.3% | ||
| Q1 24 | 13.2% | 98.4% |
每股收益（稀释后）ANIPLBRDA
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | $2.68 | ||
| Q1 25 | $0.69 | $1.87 | ||
| Q4 24 | $-0.45 | $2.04 | ||
| Q3 24 | $-1.27 | $0.99 | ||
| Q2 24 | $-0.14 | $1.36 | ||
| Q1 24 | $0.82 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $180.0M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | $540.7M | $10.4B |
| 总资产 | $1.4B | $16.6B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ANIPLBRDA
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | $180.0M | ||
| Q1 25 | $149.8M | $226.0M | ||
| Q4 24 | $144.9M | $163.0M | ||
| Q3 24 | $145.0M | $168.0M | ||
| Q2 24 | $240.1M | $73.0M | ||
| Q1 24 | $228.6M | $108.0M |
总债务ANIPLBRDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | — | $3.8B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | — | $3.6B | ||
| Q1 24 | — | $3.6B |
股东权益ANIPLBRDA
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | — | ||
| Q2 25 | $436.8M | $10.4B | ||
| Q1 25 | $418.6M | $10.1B | ||
| Q4 24 | $403.7M | $9.8B | ||
| Q3 24 | $405.9M | $9.5B | ||
| Q2 24 | $455.8M | $9.3B | ||
| Q1 24 | $452.0M | $9.1B |
总资产ANIPLBRDA
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.3B | $16.6B | ||
| Q1 25 | $1.3B | $17.0B | ||
| Q4 24 | $1.3B | $16.7B | ||
| Q3 24 | $1.3B | $16.3B | ||
| Q2 24 | $920.8M | $16.0B | ||
| Q1 24 | $914.5M | $15.7B |
负债/权益比ANIPLBRDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $91.0M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $37.0M |
| 自由现金流率自由现金流/营收 | 11.8% | 14.2% |
| 资本支出强度资本支出/营收 | 0.5% | 20.7% |
| 现金转化率经营现金流/净利润 | 1.10× | 0.24× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $-49.0M |
8季度趋势，按日历期对齐
经营现金流ANIPLBRDA
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | — | ||
| Q2 25 | $75.8M | $91.0M | ||
| Q1 25 | $35.0M | $78.0M | ||
| Q4 24 | $15.9M | $1.0M | ||
| Q3 24 | $12.5M | $24.0M | ||
| Q2 24 | $17.4M | $27.0M | ||
| Q1 24 | $18.3M | $52.0M |
自由现金流ANIPLBRDA
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | $37.0M | ||
| Q1 25 | $32.5M | $13.0M | ||
| Q4 24 | $13.5M | $-63.0M | ||
| Q3 24 | $7.7M | $-36.0M | ||
| Q2 24 | $13.0M | $-35.0M | ||
| Q1 24 | $13.7M | $-9.0M |
自由现金流率ANIPLBRDA
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | 14.2% | ||
| Q1 25 | 16.5% | 4.9% | ||
| Q4 24 | 7.1% | -24.0% | ||
| Q3 24 | 5.2% | -13.7% | ||
| Q2 24 | 9.4% | -14.2% | ||
| Q1 24 | 10.0% | -3.7% |
资本支出强度ANIPLBRDA
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | 20.7% | ||
| Q1 25 | 1.3% | 24.4% | ||
| Q4 24 | 1.3% | 24.3% | ||
| Q3 24 | 3.2% | 22.9% | ||
| Q2 24 | 3.2% | 25.2% | ||
| Q1 24 | 3.3% | 24.9% |
现金转化率ANIPLBRDA
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 0.24× | ||
| Q1 25 | 2.23× | 0.29× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | 1.00× | 0.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
LBRDA
暂无分部数据
